Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment

Renal Impairment Clinical Trial

Official title:

A Phase I, Open Label, Multicenter, Single Dose Study to Evaluate the Pharmacokinetics of Dabrafenib in Healthy Subjects With Normal Renal Function and Subjects With Impaired Renal Function

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02852239
• Other study ID #: CDRB436A2106
• Status: Completed
• Phase: Phase 1
• Start date: December 19, 2016
• Est. completion date: September 27, 2019

Study information

• Verified date: July 2020
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To characterize the pharmacokinetics and safety of dabrafenib following a single 100 mg oral dose in subjects with severe renal impairment and end stage renal disease not on dialysis.

Description:

The main objective of this trial is to evaluate the pharmacokinetics of dabrafenib and metabolites after a single oral dose of dabrafenib in subjects with renal impairment as compared to healthy subjects with normal renal function. This was a single-dose, open-label, parallel group single dose study to evaluate the pharmacokinetics (PK) and safety of a single oral dose of dabrafenib 100 mg in subjects with severe RI or ESRD compared to matched healthy subjects with normal renal function (control group). The study consisted of a screening period, a treatment period and a follow-up period. The Screening period started up to 28 days prior to dosing. Subjects who satisfied the inclusion/exclusion criteria at screening were admitted for baseline evaluations, which was done locally by the investigator. In the treatment period, subjects received a single 100 mg oral dose of dabrafenib administered as two 50 mg capsules with a whole glass of non-carbonated water (approximately 240 mL) in the morning of Day 1 following an overnight fast (minimum 10 hours). Subjects were confined to the study facility from Day -1 to Day 5, for collection of serial blood and urine samples. Subjects were discharged on Day 5. In the follow-up period a telephone call was made to subjects 30 days post-dose to evaluate subject safety during the weeks after discharge from the facility. Adverse events occurring prior to Day 30 were followed until resolution or until judged to be permanent. Subjects returned to the clinic on Days 90 and 180 for the post-dose dermatological examination follow up. For this study, the terms "investigational drug", "study drug" or "study treatment" refer to dabrafenib, administered as a single dose.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: September 27, 2019
• Est. primary completion date: September 27, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

All subjects:

• Females must be of non-childbearing potential or must have negative pregnancy results at screening
• Good health as determined by lack of clinically significant findings
• Subjects must have a BMI between 18.0 kg/m2 and 38.0 kg/m2, with a body weight of at least 50 kg and no more than 140 kg
• Vitals signs within normal range
• Laboratory values at screening within local normal ranges or considered non-clinically significant Additional criteria for renal impairment subjects: -Stable renal disease without evidence of renal progression in the past 28 days prior to dosing

Additional criteria for healthy matched subjects:

• Matched to at least 1 renal impairment subject by race, age (+/-10 years), gender and weight (+/-10%)
• An absolute GFR of at least 90 ml/min

Exclusion Criteria for all subjects:

• Significant acute illness within the two weeks prior to dosing
• History or current diagnosis of cardiac disease indicating significant risk such as uncontrolled or significant cardiac disease or clinically significant ECG abnormalities
• Subjects will be screened for drugs of abuse
• History of drug or alcohol abuse within 6 months prior to dosing or evidence of such abuse as indicated by laboratory values at screening or baseline.
• Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs.
• History of malignancy of any organ system, treated or untreated, within 5 years, regardless of where there is recurrence or metastases.
• Use of drugs known to prolong the QT interval within 4 weeks prior to dosing and for the duration of the study.
• Use of drugs know to affect CYP3A4 and/or CYP2C8 including both (strong or moderate) inhibitors and inducers, within 7 days prior to dosing or during the current study are prohibited

Related Conditions & MeSH terms

• Renal Impairment
• Renal Insufficiency

Intervention

Drug:
• dabrafenib
Single dose dabrafenib 100 mg

Locations

Country	Name	City	State
United States	Hassman Research Institute	Berlin	New Jersey
United States	Omega Research Consultants LLC	DeBary	Florida
United States	Wake Research Associates Oncology	Raleigh	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum plasma concentration (Cmax)	The maximum (peak) observed plasma drug concentration after a single dose of dabrafenib	Predose through 96 hours postdose
Primary	Area under the curve (AUClast)	AUClast is the area under the curve calculated to the last quantifiable concentration point after a single dose of dabrafenib	Predose through 96 hours postdose
Primary	Area under the curve (AUFinf)	AUCinf is the area under the plasma concentration time curve extrapolated to infinity after a single dose of dabrafenib	Predose through 96 hours postdose
Primary	Systemic drug clearance (CL/F)	Systemic clearance from plasma of dabrafenib after a single dose	Predose through 96 hours postdose
Primary	Time to reach maximum concentration (Tmax)	The time to reach maximum (peak) concentration of dabrafenib after a single dose	Predose through 96 hours postdose
Primary	Terminal elimination rate (Lambda_z)	Terminal elimination rate of dabrafenib after a single dose	Predose through 96 hours postdose
Primary	Elimination half-life (T1/2)	Elimination half-life of dabrafenib after a single dose	Predose through 96 hours postdose
Primary	Volume of distribution (Vz/F)	The apparent volume of distribution during the terminal elimination phase of dabrafenib after a single dose	Predose through 96 hours postdose
Primary	Unchanged drug excreted in urine (Aet)	The amount of unchanged dabrafenib excreted in urine after a single dose	Predose through 96 hours postdose
Primary	Renal clearance (CLr)	Renal clearance of dabrafenib calculated using plasma AUC after a single dose	Predose through 96 hours postdose
Secondary	Number of subjects with adverse events	Assess the safety of a single dose of dabrafenib through AE reports of subjects from drug administration through 30 days postdose	Time of drug administration through 30 days postdose
Secondary	Number of subjects with abnormal lab values related to study drug	Assess the safety of a single dose of dabrafenib through hematology and chemistry blood tests	Time of study drug administration through 30 days postdose
Secondary	Number of subjects with abnormal blood pressure related to study drug	Assess the safety of a single dose of dabrafenib by monitoring changes in blood pressure	Time of study drug administration through 30 days postdose
Secondary	Changes in electrocardiogram (ECG)	Assess the safety of a single dose of dabrafenib by monitoring changes in ECG	Time of study drug administration through 30 days postdose
Secondary	Number of subjects with abnormal pulse rate related to study drug	Assess the safety of a single dose of dabrafenib by monitoring changes in heart rate	Time of study drug administration through 30 days postdose
Secondary	Number of subjects with abnormal respiratory rate related to study drug	Assess the safety of a single dose of dabrafenib by monitoring changes in respiratory rate	Time of study drug administration through 30 days postdose

External Links

•   CDRB436A2106 sudy results on the Novartis results database